CAR-T cells plus half-matched stem cell transplant for high-risk blood cancer
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests giving special immune cells (CAR-T cells) that target a protein called CD19 on cancer cells, followed by a half-matched stem cell transplant, to treat high-risk blood cancers. The treatment aims to improve outcomes by using the CAR-T cells to reduce disease before the transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need to have a high-risk blood cancer or minimal residual disease (MRD).
- Your cancer must be CD19 positive.
- You need a suitable half-matched (haploidentical) donor available.
- Your heart, lungs, and kidneys must be functioning well enough, and you must be generally healthy.
- You must not be pregnant, have active other cancers or uncontrolled infections, and must not have had certain central nervous system involvement.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using specially modified immune cells (CAR-T cells) to fight certain blood cancers that have come back or haven't improved with standard treatments. It may help your body's own immune system attack the cancer cells.
This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.
This trial tests a personalized cancer treatment called CAR-T therapy. It uses your own immune cells, which are modified in a lab to fight your specific type of blood cancer, and then given back to you. The goal is to see if this treatment is safe and feasible when produced locally.
This trial tests a new type of immunotherapy called CAR-T cells, which are engineered to attack cancer cells that have certain markers (CD19 or BCMA). It is for people with blood cancers like multiple myeloma or certain lymphomas that have not responded to multiple prior treatments. The goal is to see if this treatment can help when other options have failed.
This study tests a personalized cell treatment called CAR-T for people whose blood cancer (like lymphoma, leukemia, or chronic lymphocytic leukemia) has come back or not gotten better after standard treatment. The therapy uses your own immune cells, modified in a lab, to find and fight the cancer.
This trial tests a new immune cell therapy (CAR-T) that targets two markers on high-risk plasma cell cancers. It aims to see if this treatment is safe and helpful for people with aggressive or resistant forms of this disease.
Hear when a new Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.